Fresh perspectives on clinical terminologies, code mapping, and patient insights from the experts at IMO.
Monoclonal antibody infusion therapy is showing great promise as a treatment option for specific COVID-19 patients. Finding those patients, however, can be cumbersome and time consuming without precisely defined value sets.
In creating not just one, but multiple, vaccines for the SARS-CoV-2 virus in under a year, pharmaceutical researchers and developers achieved a remarkable feat. But there’s still a challenge ahead: distributing and administering the vaccine across the country, while also managing a flood of inoculation data.
In December 2020, the FDA granted emergency use authorization for the first COVID-19 vaccine, initiating the largest inoculation effort in US history. But, three months later the rollout has not gone as smoothly as hoped – putting more stress on already overburdened health systems and providers.
In late August, the federal government predicted a limited amount of COVID-19 vaccines would be available at the beginning of November, and that healthcare systems in all 50 states should be ready to implement an inoculation plan by this date. However, only targeted populations will be eligible for receipt – begging the questions: who should be immunized first, and how should existing epidemiological data be used to help guide the decision-making process?
As our health systems continue to respond to the COVID-19 pandemic, clear communication is crucial. Recent changes in reporting regulations from the federal government have led to confusion, which runs the risk of incomplete or inaccurate data collection about the spread and severity of the SARS-CoV-2 virus. We break down the changes, and subsequent concerns about them, below.
